Luis Raez
Overview
Explore the profile of Luis Raez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
347
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ruiz-Patino A, Rojas L, Zuluaga J, Arrieta O, Corrales L, Martin C, et al.
Clin Transl Oncol
. 2024 Apr;
26(8):1856-1871.
PMID: 38581481
Latin American populations, characterized by intricate admixture patterns resulting from the intermingling of ancestries from European, Native American (NA) Asian, and African ancestries which result in a vast and complex...
2.
Motta-Guerrero R, Leon Garrido-Lecca A, Failoc-Rojas V, Calle-Villavicencio A, Villacorta-Carranza R, Huerta-Collado Y, et al.
Front Oncol
. 2024 Feb;
13:1335373.
PMID: 38322283
Background: The EGFR gene encodes a protein that stimulates molecular pathways that allow the growth and development of the tumor microenvironment. The current preferred tyrosine kinase inhibitor (TKI) for the...
3.
Chamorro D, Cardona A, Rodriguez J, Ruiz-Patino A, Arrieta O, Moreno-Perez D, et al.
Target Oncol
. 2023 Apr;
18(3):425-440.
PMID: 37017806
Background: Epidermal growth factor receptor (EGFR) mutations (EGFRm) represent one of the most common genomic alterations identified among patients with non-small cell lung cancer (NSCLC). Several targeted agents for patients...
4.
Nagasaka M, Ohe Y, Zhou C, Choi C, Yang N, Liu G, et al.
Future Oncol
. 2023 Mar;
19(2):123-135.
PMID: 36877099
Crizotinib and entrectinib have been approved to treat fusion-positive (ROS1) non-small-cell lung cancer. However, unmet needs remain, including treatment of patients with resistance mutations, efficacy in brain metastasis and avoidance...
5.
Ruiz R, Galvez-Nino M, Roque K, Montes J, Nunez M, Raez L, et al.
Front Oncol
. 2022 Oct;
12:910117.
PMID: 36263208
Background: Lung cancer in the young is a rare entity of great interest due to the high frequency of targetable mutations. In this study, we explored the genomic landscape of...
6.
Caglevic C, Rolfo C, Gil-Bazo I, Cardona A, Sapunar J, Hirsch F, et al.
JCO Glob Oncol
. 2022 Aug;
8:e2200123.
PMID: 35994695
On February 24, 2022, a war began within the Ukrainian borders. At least 3.0 million Ukrainian inhabitants have already fled the country. Critical infrastructure, including hospitals, has been damaged. Children...
7.
Cardona A, Ruiz-Patino A, Recondo G, Martin C, Raez L, Samtani S, et al.
Clin Lung Cancer
. 2022 Jul;
23(6):522-531.
PMID: 35798634
Introduction: Osimertinib is a third generation EGFR-TKI inhibitor approved in the first-line setting for patients with advanced non-small cell lung cancer (NSCLC). Additionally, it represents the treatment of choice in...
8.
Cordeiro de Lima V, Corassa M, Saldanha E, Freitas H, Arrieta O, Raez L, et al.
Lung Cancer
. 2022 Jun;
170:114-121.
PMID: 35753125
Background: Mutations in STK11 (STK11) and, frequently co-occurring, KEAP1 mutations (KEAP1) are associated with poor survival in metastatic Non-small Cell Lung Cancer (mNSCLC) patients treated with immunotherapy. However, there are...
9.
Sadler D, Fradley M, Ismail-Khan R, Raez L, Bhandare D, Elson L, et al.
JACC CardioOncol
. 2021 Aug;
2(3):535-538.
PMID: 34396265
No abstract available.
10.
Sands J, Mandrekar S, Kozono D, Oxnard G, Hillman S, Wigle D, et al.
Immunotherapy
. 2021 Apr;
13(9):727-734.
PMID: 33878954
Non-small-cell lung cancer (NSCLC) causes significant mortality each year. After successful resection of disease stage IB (>4 cm) to IIIA (per AJCC 7), adjuvant platinum-based chemotherapy improves median overall survival...